Tel Aviv University Neuroimmunology Laboratory
Research to Prevent Cancer Recurrence
and Metastatic Disease
Pancreatic Cancer
Innovative research treatment for pancreatic cancer patients undergoing surgery, to prevent cancer recurrence and prevent the development of cancer metastases
-
The treatment is provided free of charge.
-
The treatment is provided in addition to and does not replace existing treatments.
-
Treatment begins 5 days before surgery.
-
The treatment is based on existing drugs marketed in Israel and internationally.
Who the research is intended for
-
Diagnosis of primary pancreatic cancer, stage 1 or 2 disease (without evidence of metastasis)
-
Patients scheduled to undergo surgery to remove the tumor
-
Women and men aged 20 to 85
Who the research is not intended for
-
Patients with active asthma
-
Regular use of beta-blocker or NSAID medications or sensitivity to these medications.
Medical centers where
The research is underway
-
Shamir Medical Center (Asaf Harofeh), Tzirifin.
-
Principal Investigator: Prof. Oded Zamora.
-
Sheba Medical Center, Tel Hashomer, Ramat Gan.
-
Principal Investigator: Prof. Aviram Nissan.
*A full eligibility check for the study will be carried out at the medical center.
When you arrive at your next appointment with your doctor, ask him/her about joining the study!